BRPI0412453A - uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo - Google Patents

uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo

Info

Publication number
BRPI0412453A
BRPI0412453A BRPI0412453-7A BRPI0412453A BRPI0412453A BR PI0412453 A BRPI0412453 A BR PI0412453A BR PI0412453 A BRPI0412453 A BR PI0412453A BR PI0412453 A BRPI0412453 A BR PI0412453A
Authority
BR
Brazil
Prior art keywords
acceptable salt
ascorbic acid
physiologically acceptable
fungal
patients
Prior art date
Application number
BRPI0412453-7A
Other languages
English (en)
Inventor
Federico Mailland
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of BRPI0412453A publication Critical patent/BRPI0412453A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)

Abstract

"USO DO áCIDO ASCóRBICO OU UM SAL FISIOLOGICAMENTE ACEITáVEL DO MESMO". A presente invenção está direcionada a composições contendo ácido ascórbico ou um sal fisiologicamente aceitável do mesmo para a preparação de uma formulação útil para a prevenção de recorrências de infecções fúngicas ou de superinfecções fúngicas, em pacientes em risco.
BRPI0412453-7A 2003-07-22 2004-05-21 uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo BRPI0412453A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03077314A EP1500394A1 (en) 2003-07-22 2003-07-22 Pharmaceutical compositions comprising ascorbic acid or the treatment of fungal superinfections and fungal recurrences
PCT/EP2004/005559 WO2005013971A1 (en) 2003-07-22 2004-05-21 Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences

Publications (1)

Publication Number Publication Date
BRPI0412453A true BRPI0412453A (pt) 2006-10-17

Family

ID=33483977

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412453-7A BRPI0412453A (pt) 2003-07-22 2004-05-21 uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo

Country Status (22)

Country Link
US (1) US7863326B2 (pt)
EP (2) EP1500394A1 (pt)
JP (1) JP4791358B2 (pt)
KR (1) KR101100713B1 (pt)
CN (1) CN100540000C (pt)
AR (1) AR045070A1 (pt)
AT (1) ATE413171T1 (pt)
BR (1) BRPI0412453A (pt)
CA (1) CA2528879A1 (pt)
CY (1) CY1108684T1 (pt)
DE (1) DE602004017613D1 (pt)
DK (1) DK1646378T3 (pt)
EA (1) EA010241B1 (pt)
ES (1) ES2314406T3 (pt)
HR (1) HRP20090022T3 (pt)
MX (1) MXPA05013798A (pt)
PL (1) PL1646378T3 (pt)
PT (1) PT1646378E (pt)
SI (1) SI1646378T1 (pt)
UA (1) UA88446C2 (pt)
WO (1) WO2005013971A1 (pt)
ZA (1) ZA200509851B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1850829A4 (en) * 2005-02-03 2012-12-26 Taro Pharmaceuticals Usa Inc NEW PROPOLFOL COMPOSITION WITH ASCORBIC ACID OR PHARMACEUTICALLY USEFUL SALTS
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US20090197946A1 (en) * 2008-01-31 2009-08-06 Joseph Di Bartolomeo Composition and method for treatment of inflamation and infections of the genitalia, contraceptive and the prophylaxis of sexually transmitted diseases
FI20095550A0 (fi) * 2009-05-19 2009-05-19 Bayer Schering Pharma Oy Vaginaalinen antojärjestelmä
CN102933713B (zh) * 2010-04-08 2015-05-13 佛罗里达大学研究基金会有限公司 具有多功能的瞬时表达病毒载体体系
US12612370B2 (en) 2011-03-02 2026-04-28 Thermolife International, Llc Amino acid compositions
DE102012009057A1 (de) 2012-05-09 2013-11-14 Dr. Arabin GmbH & Co. KG Rotationspessar mit zusätzlicher Wirkstoffkomponente
FR3018193B1 (fr) * 2014-03-10 2017-09-08 Probionov Comprime vaginal muco-adhesif a liberation prolongee
JP2024541338A (ja) 2020-11-12 2024-11-08 サーモライフ インターナショナル， エルエルシー 血中酸素飽和度を増大させる方法
US11865139B2 (en) * 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
AU2022220004A1 (en) 2021-02-11 2023-08-17 Thermolife International, Llc A method of administering nitric oxide gas
WO2025245573A1 (en) * 2024-05-28 2025-12-04 Liquim Limited Formulation and hydrogels formed therefrom
CN120600339B (zh) * 2025-08-05 2025-09-30 中国人民解放军空军军医大学 一种抗真菌药物肝毒性检测方法及系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229430A (en) * 1978-08-21 1980-10-21 Fahim Mostafa S Oral composition for improving oral health
JPH01125306A (ja) * 1987-11-09 1989-05-17 Daiichi Seimo Kk 赤腐れ菌の防除剤
EP0527241B1 (de) * 1991-07-15 1994-03-16 Artesan Pharma Gesellschaft mit beschränkter Haftung Verwendung der Ascorbinsäure zur Zubereitung von Arzneimitteln zur Anwendung im Genitalbereich
US5425944A (en) * 1992-10-27 1995-06-20 Harich; Jakob Antimicrobial grapefruit extract
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
CN1245074A (zh) * 1998-04-26 2000-02-23 曾忠铭 减弱阴道酸度的药剂和用途
US6153635A (en) * 1998-11-20 2000-11-28 Upmalis; David H. Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate
JP2000169370A (ja) * 1998-12-09 2000-06-20 Frontier:Kk 肉食動物用皮膚疾患治療薬及び健康食品
DE29900513U1 (de) * 1999-01-14 2000-08-10 RST Icking GmbH, 82057 Icking Schuh- bzw. Fuß-Hygienemittel
RU2150935C1 (ru) * 1999-06-22 2000-06-20 Московский государственный медико-стоматологический университет Защитно-профилактический крем
US6391330B1 (en) * 2000-05-11 2002-05-21 Michael A. Ross Proanthocyanidins and ascorbic acid composition for topical application to human respiratory and oral mucosa
US20030130225A1 (en) * 2001-10-16 2003-07-10 Nawaz Ahmad Novel methods of treating local fungal and bacterial infections

Also Published As

Publication number Publication date
MXPA05013798A (es) 2006-06-27
CA2528879A1 (en) 2005-02-17
HK1092693A1 (en) 2007-02-16
CY1108684T1 (el) 2014-04-09
SI1646378T1 (sl) 2009-02-28
ZA200509851B (en) 2007-03-28
WO2005013971A1 (en) 2005-02-17
PL1646378T3 (pl) 2009-04-30
EA010241B1 (ru) 2008-06-30
ATE413171T1 (de) 2008-11-15
CN100540000C (zh) 2009-09-16
JP4791358B2 (ja) 2011-10-12
EP1500394A1 (en) 2005-01-26
UA88446C2 (uk) 2009-10-26
DK1646378T3 (da) 2009-01-19
EP1646378A1 (en) 2006-04-19
JP2006528138A (ja) 2006-12-14
ES2314406T3 (es) 2009-03-16
US7863326B2 (en) 2011-01-04
KR20060040603A (ko) 2006-05-10
CN1812781A (zh) 2006-08-02
AR045070A1 (es) 2005-10-12
KR101100713B1 (ko) 2011-12-30
US20070037880A1 (en) 2007-02-15
HRP20090022T3 (hr) 2009-02-28
EP1646378B1 (en) 2008-11-05
EA200600176A1 (ru) 2006-06-30
PT1646378E (pt) 2008-12-17
DE602004017613D1 (de) 2008-12-18

Similar Documents

Publication Publication Date Title
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
BRPI0507653A (pt) derivados de imidazopiridina e imidazopiridina formulação farmacêutica compreendendo os mesmos e uso
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
CY1108684T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν ασκορβικο οξυ για τη θεραπεια μυκητοειδων υπερμολυνσεων και μυκητοειδων επανεμφανισεων
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
BRPI0411702B8 (pt) uso de ácido hialurônico para preparar composições para o tratamento de aftas da cavidade oral
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
BRPI0618370A2 (pt) formulação aerossol de medicamento, uso do mesmo e kit de inalação
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
BRPI0417003A (pt) uso de derivados de ácido pentadienóico para o tratamento de hiperuricemia
ATE346080T1 (de) Steroid-verbindungen mit anti-tumoraler wirkung
BR0215498A (pt) Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes
PE20040697A1 (es) Composicion farmaceutica que comprende un antagonista de ltb4 y un inhibidor de la cox-2 o cox-1/2 combinado
IT1314204B1 (it) Complessi di rutenio con elevata attivita' antitumorale

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/375, 31/10; A61P 31/00, 31/10

Ipc: A61K 31/375 (2011.01), A61K 31/10 (2011.01), A61P

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements